<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638300</url>
  </required_header>
  <id_info>
    <org_study_id>sor421306ctil</org_study_id>
    <nct_id>NCT00638300</nct_id>
  </id_info>
  <brief_title>Removal of Ligand-bound Iron During Intravenous (IV) Iron Administration in Hemodialysis (HD)</brief_title>
  <official_title>Removal of Ligand-bound Iron During Intravenous Iron Administration in Hemodialysis by Large Pore Dialyzers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bnai Zion Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rivka Ziv Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Soroka University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study's hypothesis is that HD with large pore dialyzers remove to the dialysate iron
      which is bound to potentially dialyzable ligands, after it's release from intravenous iron
      compound administered during hemodialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most hemodialysis(HD) patients receive during HD intravenous iron compounds, which are
      composed of an iron core and a sugar polymer shell.

      A small percentage of iron from the iron compound is released to the plasma, and may be
      associated with increased oxidative stress and protein oxidation. The study's hypothesis is
      that HD with large pore dialyzers may remove to the dialysate iron which is bound to
      potentially dialyzable ligands, after it's release from intravenous iron compound
      administered during hemodialysis.

      Ligand-bound iron removal is also hypothesized to be affected by dialysate calcium and
      bicarbonate concentrations, which may affect iron-ligand binding.

      Study Specific aims are:

      To evaluate

        1. Iron removal assessing dialysate iron levels.

        2. Effect of iron removal and it's associated experimental conditions on patient status,
           assessing plasma AOPP levels and inflammation related parameters

      Study include 3 parts

        1. Comparing large to small pore dialyzers

           (To achieve baseline uniform conditions, patients will be on uniform dialysate
           bicarbonate and calcium concentrations of 33 mEq/L and 3 mEq/L,respectively, using large
           pore dialyzers during this part, besides the 2 HD sessions evaluating low pore
           dialyzers)

           and after few week break

           Using large pore dialyzers to compare

        2. Low to high dialysate bicarbonate concentration (using uniform dialysate calcium
           concentrations of 3 mEq/L)

           and after few week break

        3. Low to high dialysate calcium concentrations concentration (using uniform dialysate
           bicarbonate of 33 mEq/L)

      In each part, patients will be first evaluated in HD without IV iron administration, which
      will serve as a control for evaluation after a week in HD with IV iron administration.

      In each part, patients will be randomized to start either with one of the 2 experimental
      conditions, and after 1 week without evaluation will cross-over to the other experimental
      condition.

      Patients may participate in 1,2 or the 3 parts of study depending on their will and
      condition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Dialysate Iron levels 2. Plasma levels of advanced oxidation protein products(AOPP)</measure>
    <time_frame>Before HD, after 1 hour of HD with or without IV iron and at end of HD</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Hemodialysis Patients</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>large pore dialyzers (FX80, Fresenius, Germany)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>small pore dialyzers ( F8HPS, Fresenius, Germany)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dialysate bicarbonate concentration of 33 mEq/l</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dialysate bicarbonate concentration of 40 mEq/l</description>
  </arm_group>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dialysate calcium concentration of 3 mEq/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dialysate calcium concentration of 2.5 mEq/L</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>large pore (FX80) compared to small pore dialyzer (F8HPS)</intervention_name>
    <description>Effect of pore size</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dialysate bicarbonate of 33 mEq/L compared to 40 mEq/L</intervention_name>
    <description>Effect of dialysate bicarbonate concentration</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dialysate calcium of 3 mEq/L compared to 2.5 mEq/L</intervention_name>
    <description>Effect of dialysate calcium concentration</description>
    <arm_group_label>I</arm_group_label>
    <arm_group_label>II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hemodialysis patients

        Exclusion Criteria:

          -  Acute disease (infection, thrombosis, ischemia, bleeding) Hepatitis B, Hepatitis C or
             HIV

          -  Intravenous iron administration or packed red cell transfusion in the last 3 weeks
             prior to the study

          -  Refusal to comply with limitations in fat containing food during HD with plasma
             sampling for AOPP evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Tovbin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soroka University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HD unit in Department of Nephrology in Soroka Universty Medical Center</name>
      <address>
        <city>Beer-sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HD unit in Bnai-zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rivka Ziv Medical center</name>
      <address>
        <city>Zefat</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2008</study_first_submitted>
  <study_first_submitted_qc>March 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2008</study_first_posted>
  <last_update_submitted>July 11, 2010</last_update_submitted>
  <last_update_submitted_qc>July 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>David Tovbin MD</name_title>
    <organization>Soroka University Medical Center</organization>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>iron</keyword>
  <keyword>inflammation</keyword>
  <keyword>atomic absorption</keyword>
  <keyword>dialysate</keyword>
  <keyword>advanced oxidation protein products</keyword>
  <keyword>large pore dialysate</keyword>
  <keyword>bicarbonate</keyword>
  <keyword>calcium</keyword>
  <keyword>citrate</keyword>
  <keyword>ligand</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

